Overview

Cognition, Functioning and Quality of Life

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
People affected by schizophrenia often experience poor concentration, lapses in memory and difficulty with completing tasks; and this set of problems are known as neuro-cognitive deficits. Traditional medications used in the treatment of schizophrenia have not been particularly useful in improving these problems, while the recently introduced medications are expected to be superior in this respect. The proposed research study is designed to assess the effect of two of the new medications (Zyprexa and Seroquel) in improving the neurocognitive deficits associated with schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborator:
AstraZeneca
Treatments:
Olanzapine
Quetiapine Fumarate